A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in Europe

IF 3.4 3区医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL

Advances in Therapy Pub Date : 2025-03-19 DOI:10.1007/s12325-025-03152-4

Emmanuelle Kaltenbach, Ana Maria Rodriguez-Leboeuf, Patrick Cabri, Mickael Henry-Szatkowski, Mehmet Inceer, Emma Karim, Valérie Perrot, Giuseppe Fallara, Matteo Ferro

{"title":"A Noninterventional, Cross-Sectional Study to Assess Patient Prostate Cancer Treatment Preferences and Experiences in Europe","authors":"Emmanuelle Kaltenbach, Ana Maria Rodriguez-Leboeuf, Patrick Cabri, Mickael Henry-Szatkowski, Mehmet Inceer, Emma Karim, Valérie Perrot, Giuseppe Fallara, Matteo Ferro","doi":"10.1007/s12325-025-03152-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>Gonadotropin-releasing hormone (GnRH) agonist injection frequency does not affect prostate cancer treatment efficacy; however, it may influence treatment satisfaction, adherence, and overall healthcare utilization. This study addressed the limited information available on real-world patient experience with GnRH treatments by surveying a diverse population of patients with prostate cancer in Europe.</p><h3>Methods</h3><p>This noninterventional, cross-sectional study included adults with locally advanced or metastatic prostate cancer in Belgium, France, Italy, Spain, and the UK. Data were collected via a one-time self-administered electronic survey (October–December 2023) that assessed patient preferences for injection frequency, satisfaction, healthcare resource utilization, and involvement in treatment decision-making.</p><h3>Results</h3><p>Of 414 participants, 53.9% preferred a 6-month injection frequency, while 27.3% preferred a 3-month frequency. Among those receiving injections every 6 months, 77.0% were satisfied; 62.7% of those receiving injections every 3 months were satisfied. Two-thirds of participants (65.7%) were aware of different frequencies of injections. Among those who preferred a 3-month injection frequency, routine and perceived control over their disease were important factors, with 38.1% receiving injections at the same frequency as doctor visits. Among those preferring a 6-month frequency, convenience and routine were important; however, 7.2% indicated that their preference was based on a dislike or fear of injections. Of those with no preference, 60.3% indicated that this was because they deferred to their doctor’s advice. Most patients required transport to their injection appointment, and of those who were employed, 79.2% required time off from work. Accompaniment to an injection appointment was also important, with 66.2% of patients never attending alone.</p><h3>Conclusion</h3><p>The high satisfaction rates, particularly among those receiving injections every 6 months, suggest that less-frequent injections may be more convenient and preferable for many patients. These insights can help to guide patient-centric care and treatment decisions in prostate cancer management.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 5","pages":"2314 - 2334"},"PeriodicalIF":3.4000,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03152-4.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03152-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Gonadotropin-releasing hormone (GnRH) agonist injection frequency does not affect prostate cancer treatment efficacy; however, it may influence treatment satisfaction, adherence, and overall healthcare utilization. This study addressed the limited information available on real-world patient experience with GnRH treatments by surveying a diverse population of patients with prostate cancer in Europe.

Methods

This noninterventional, cross-sectional study included adults with locally advanced or metastatic prostate cancer in Belgium, France, Italy, Spain, and the UK. Data were collected via a one-time self-administered electronic survey (October–December 2023) that assessed patient preferences for injection frequency, satisfaction, healthcare resource utilization, and involvement in treatment decision-making.

Results

Of 414 participants, 53.9% preferred a 6-month injection frequency, while 27.3% preferred a 3-month frequency. Among those receiving injections every 6 months, 77.0% were satisfied; 62.7% of those receiving injections every 3 months were satisfied. Two-thirds of participants (65.7%) were aware of different frequencies of injections. Among those who preferred a 3-month injection frequency, routine and perceived control over their disease were important factors, with 38.1% receiving injections at the same frequency as doctor visits. Among those preferring a 6-month frequency, convenience and routine were important; however, 7.2% indicated that their preference was based on a dislike or fear of injections. Of those with no preference, 60.3% indicated that this was because they deferred to their doctor’s advice. Most patients required transport to their injection appointment, and of those who were employed, 79.2% required time off from work. Accompaniment to an injection appointment was also important, with 66.2% of patients never attending alone.

Conclusion

The high satisfaction rates, particularly among those receiving injections every 6 months, suggest that less-frequent injections may be more convenient and preferable for many patients. These insights can help to guide patient-centric care and treatment decisions in prostate cancer management.

查看原文本刊更多论文

一项评估欧洲前列腺癌患者治疗偏好和经验的非介入性横断面研究。

简介：促性腺激素释放激素（GnRH）激动剂注射频率不影响前列腺癌治疗效果；然而，它可能会影响治疗满意度、依从性和整体医疗保健利用率。本研究通过调查欧洲不同人群的前列腺癌患者，解决了关于GnRH治疗的真实患者经验的有限信息。方法：这项非介入性横断面研究包括比利时、法国、意大利、西班牙和英国的局部晚期或转移性前列腺癌的成年人。数据通过一次性自我管理的电子调查（2023年10月至12月）收集，评估患者对注射频率、满意度、医疗资源利用和参与治疗决策的偏好。结果：在414名参与者中，53.9%的人喜欢6个月的注射频率，而27.3%的人喜欢3个月的注射频率。每6个月接受一次注射，77.0%满意；每3个月接受一次注射的患者满意度为62.7%。三分之二的参与者（65.7%）知道不同的注射频率。在那些喜欢3个月注射频率的人中，常规和对疾病的控制是重要因素，38.1%的人接受注射的频率与医生就诊的频率相同。在那些喜欢6个月频率的人中，方便和常规是重要的；然而，7.2%的人表示他们的偏好是基于不喜欢或害怕注射。在没有选择的人中，60.3%表示这是因为他们遵从了医生的建议。大多数患者需要运输到他们的注射预约，而在那些受雇的人中，79.2%需要请假。注射预约时的陪伴也很重要，66.2%的患者从未单独参加过注射预约。结论：患者满意度较高，尤其是6个月一次的患者满意度较高，说明减少注射次数对许多患者来说可能更方便、更可取。这些见解有助于指导以患者为中心的护理和前列腺癌管理的治疗决策。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Advances in Therapy 医学-药学

CiteScore

7.20

自引率

2.60%

发文量

353

审稿时长

6-12 weeks

期刊介绍： Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.